Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TG02 citrate + carfilzomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Cothera Bioscience
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is an **investigational combination therapy** consisting of **TG02 citrate (zotiraciclib)**, **carfilzomib**, and **dexamethasone**. TG02 citrate (zotiraciclib) is an orally active, spectrum-selective kinase inhibitor targeting cyclin-dependent kinases (notably CDK9), JAK2, and FLT3, developed to deplete Myc and block key cancer cell signaling pathways. Carfilzomib is a second-generation epoxyketone-based proteasome inhibitor. Dexamethasone is a synthetic glucocorticoid with broad anti-inflammatory and immunosuppressive effects. The combination has been studied primarily in early-phase clinical trials for relapsed/refractory multiple myeloma, including heavily pretreated and carfilzomib-refractory populations. Zotiraciclib is under investigation and has received orphan drug status for certain cancers, but the triple combination is not approved for use.
- Brand names
- Kyprolis + dexamethasone (for the approved combination of carfilzomib + dexamethasone)
- Other names
- zotiraciclib citrate + carfilzomib + dexamethasoneTG-02 citrate + carfilzomib + dexamethasone
02
Targets
JAK2 (Janus kinase 2)GR (Glucocorticoid receptor)PSMB8 (Immunoproteasome)PSMB5 (Proteasome subunit beta Type-5)CDK9 (Cyclin-dependent kinase 9)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on TG02 citrate + carfilzomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TG02 citrate + carfilzomib + dexamethasone.